Development of a PET nanomolecular agent for the vasculomonitoring of angiogenic pathologies – THERAnanoSTICS

Osler-Weber-Rendu disease is a rare vascular dysangiogenic disease characterized by visceral arteriovenous malformations (AVM) in multiple localizations. Medical imaging plays a prominent role in the detection of AVMs and their complications. In the last decade, anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy. PET molecular imaging of the angiogenic activity could quantify the angiogenic status of AVMs, guiding therapeutic eligibility (theranostics). Nanotechnology-based imaging is expected to bring breakthroughs in diagnosis by improving imaging sensitivity and specificity. We recently developed an innovative nanoagent for PET imaging based on a self-assembling amphiphilic dendrimer functionalized against ?v?3 integrin, overexpressed in AVM. The main objective of this study is to evaluate its imaging performances in detecting angiogenic foci compared to [68Ga]Ga-RGD2 PET imaging for the first time in a swine model of angiogenic activation of the rete mirabilis.